Low long-term efficacy and tolerability of add-on rufinamide in patients with Dravet syndrome

Epilepsy and Behavior

Volumn 21, Issue 3, 2011, Pages 282-284

  Mueller, A ^a   Boor, R ^b   Coppola, G ^c   Striano, P ^d   Dahlin, M ^e   von Stuelpnagel, C ^a   Lotte, J ^a   Staudt, M ^a   Kluger, G ^a  

^a Schon Klinik Vogtareuth   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dravet syndrome; Refractory seizures; Rufinamide; SCN1A mutation

Indexed keywords

CLOBAZAM; RUFINAMIDE; SODIUM CHANNEL NAV1.1;

ABDOMINAL PAIN; ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; BEHAVIOR CHANGE; CHILD; CLINICAL ARTICLE; DECREASED APPETITE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GAIT DISORDER; HUMAN; LENNOX GASTAUT SYNDROME; MALE; NAUSEA; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SIDE EFFECT; VOMITING; WEIGHT GAIN;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MYOCLONIC EPILEPSY, JUVENILE; NERVE TISSUE PROTEINS; RETROSPECTIVE STUDIES; SEIZURES, FEBRILE; SODIUM CHANNELS; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 79959598581     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.04.057     Document Type: Article

References (27)

1. Dravet C., Bureau M., Oguni H., Fukuyama Y., Cokar O. Severe myoclonic epilepsy in infancy: Dravet syndrome. Adv Neurol 2005, 95:71-102.
2. Depienne C., Trouillard O., Saint-Martin C., et al. Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. J Med Genet 2009, 46:183-191.
3. Claes L., Del-Favero J., Ceulemans B., Lagae L., Van Broeckhoven C., De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001, 68:1327-1332.
4. Nabbout R., Dulac O. Epileptic encephalopathies: a brief overview. J Clin Neurophysiol 2003, 20:393-397.
5. Mulley J.C., Nelson P., Guerrero S., et al. A new molecular mechanism for severe myoclonic epilepsy of infancy: exonic deletions in SCN1A. Neurology 2006, 67:1094-1095.
6. Chiron C., Marchand M.C., Tran A., et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet 2000, 356:1638-1642. for the STICLO Study Group.
7. Glauser T., Kluger G., Sachdeo R., Krauss G., Perdomo C., Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008, 70:1950-1958.
8. Kluger G., Glauser T., Krauss G., Seeruthun R., Perdomo C., Arroyo S. Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand 2010, 122:202-208.
9. Wheless J.W., Vazquez B. Rufinamide: a novel broad-spectrum antiepileptic drug. Epilepsy Curr 2010, 10:1-6.
10. Wisniewski C.S. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with Lennox-Gastaut syndrome. Ann Pharmacother 2010, 44:658-667.
11. Brodie M.J., Rosenfeld W.E., Vazquez B., et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009, 50:1899-1909.
12. Cheng-Hakimian A., Anderson G.D., Miller J.W. Rufinamide: pharmacology, clinical trials, and role in clinical practice. Int J Clin Pract 2006, 60:1497-1501.
13. Coppola G., Grosso S., Franzoni E., et al. Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. Eur J Neurol 2011, 18:246-251.
14. Elger C.E., Stefan H., Mann A., Narurkar M., Sun Y., Perdomo C. A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res 2010, 88:255-263.
15. Kluger G., Kurlemann G., Haberlandt E., et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 2009, 14:491-495.
16. Kluger G., Haberlandt E., Kurlemann G., et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010, 17:546-548.
17. Palhagen S., Canger R., Henriksen O., van Parys J.A., Rivière M.E., Karolchyk M.A. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res 2001, 43:115-124.
18. Haeusler M., Kluger G., Nikanorova M. Rufinamide: a new therapeutic option for epilepsy with myoclonic absences [abstract]. Neuropediatrics 2011, 42:P003.
19. Olson H.E., Loddenkemper T., Vendrame M., et al. Rufinamide for the treatment of epileptic spasms. Epilepsy Behav 2011, 20:344-348.
20. Coppola G., Grosso S., Franzoni E., et al. Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience. Seizure 2010, 19:587-591.
21. Vendrame M., Loddenkemper T., Gooty V.D., et al. Experience with rufinamide in a pediatric population: a single center's experience. Pediatr Neurol 2010, 155-158.
22. Arroyo S. Rufinamide. Neurotherapeutics 2007, 4:155-162.
23. Yu F., Mantegazza M., Westenbroek R., et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006, 9:1142-1149.
24. Striano P., Striano S., Minetti C., Zara F. Refractory, life-threatening status epilepticus in a 3-year-old girl. Lancet Neurol 2008, 7:278-284.
25. Wakai S., Ito N., Sueoka H., Kawamoto Y., Hayasaka H., Chiba S. Severe myoclonic epilepsy in infancy and carbamazepine. Eur J Pediatr 1996, 155:724.
26. Guerrini R., Dravet C., Genton P., Belmonte A., Kaminska A., Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998, 39:508-512.
27. Saito Y., Oguni H., Awaya Y., Hayashi K., Osawa M. Phenytoin-induced choreoathetosis in patients with severe myoclonic epilepsy in infancy. Neuropediatrics 2001, 32:231-235.